218 related articles for article (PubMed ID: 12553744)
41. The clinical pharmacology of L-arginine.
Böger RH; Bode-Böger SM
Annu Rev Pharmacol Toxicol; 2001; 41():79-99. PubMed ID: 11264451
[TBL] [Abstract][Full Text] [Related]
42. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond.
Böger RH
Ann Med; 2006; 38(2):126-36. PubMed ID: 16581698
[TBL] [Abstract][Full Text] [Related]
43. Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells.
Simon A; Plies L; Habermeier A; Martiné U; Reining M; Closs EI
Circ Res; 2003 Oct; 93(9):813-20. PubMed ID: 14512444
[TBL] [Abstract][Full Text] [Related]
44. Platelet nitric oxide synthesis in uremia and malnutrition: a role for L-arginine supplementation in vascular protection?
Brunini TM; Mendes-Ribeiro AC; Ellory JC; Mann GE
Cardiovasc Res; 2007 Jan; 73(2):359-67. PubMed ID: 17078937
[TBL] [Abstract][Full Text] [Related]
45. [The L-arginine-nitric oxide system: physiology, physiopathology and clinical relevance].
Garini G; Savazzi G; Borghetti A
Recenti Prog Med; 1997 Feb; 88(2):90-9. PubMed ID: 9148375
[TBL] [Abstract][Full Text] [Related]
46. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
47. The nitric oxide pathway: is L-arginine a gate to the new millennium medicine? A meta-analysis of L-arginine effects.
Fisman EZ; Tenenbaum A; Shapira I; Pines A; Motro M
J Med; 1999; 30(3-4):131-48. PubMed ID: 17312667
[TBL] [Abstract][Full Text] [Related]
48. [L-Arginine and vascular health].
Ströhle A; von Bibra H; Hahn A
Med Monatsschr Pharm; 2016 Dec; 39(12):515-20. PubMed ID: 29979511
[TBL] [Abstract][Full Text] [Related]
49. The L-arginine nitric oxide pathway: avenue for a multiple-level approach to assess vascular function.
Rassaf T; Kleinbongard P; Kelm M
Biol Chem; 2006; 387(10-11):1347-9. PubMed ID: 17081105
[TBL] [Abstract][Full Text] [Related]
50. L-arginine: a new opportunity in the management of clinical derangements in dialysis patients.
Bellinghieri G; Santoro D; Mallamace A; Di Giorgio RM; De Luca G; Savica V
J Ren Nutr; 2006 Jul; 16(3):245-7. PubMed ID: 16825029
[TBL] [Abstract][Full Text] [Related]
51. Benefits of L-Arginine on Cardiovascular System.
Sudar-Milovanovic E; Obradovic M; Jovanovic A; Zaric B; Zafirovic S; Panic A; Radak D; Isenovic ER
Mini Rev Med Chem; 2016; 16(2):94-103. PubMed ID: 26471966
[TBL] [Abstract][Full Text] [Related]
52. Endothelial cell dysfunction in a model of oxidative stress.
Jin L; Abou-Mohamed G; Caldwell RB; Caldwell RW
Med Sci Monit; 2001; 7(4):585-91. PubMed ID: 11433181
[TBL] [Abstract][Full Text] [Related]
53. Vascular changes in cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high-sodium diet.
Lassila M; Santisteban J; Finckenberg P; Salmenperä P; Riutta A; Moilanen E; Virtanen I; Vapaatalo H; Nurminen ML
J Physiol Pharmacol; 2001 Mar; 52(1):21-38. PubMed ID: 11321510
[TBL] [Abstract][Full Text] [Related]
54. Arginine and endothelial and vascular health.
Gornik HL; Creager MA
J Nutr; 2004 Oct; 134(10 Suppl):2880S-2887S; discussion 2895S. PubMed ID: 15465805
[TBL] [Abstract][Full Text] [Related]
55. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
Sydow K; Mondon CE; Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S35-43. PubMed ID: 16444867
[TBL] [Abstract][Full Text] [Related]
56. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
[TBL] [Abstract][Full Text] [Related]
57. Decreased plasma concentrations of L-hydroxy-arginine as a marker of reduced NO formation in patients with combined cardiovascular risk factors.
Garlichs CD; Beyer J; Zhang H; Schmeisser A; Plötze K; Mügge A; Schellong S; Daniel WG
J Lab Clin Med; 2000 May; 135(5):419-25. PubMed ID: 10811058
[TBL] [Abstract][Full Text] [Related]
58. Nitric oxide and vascular insulin resistance.
Wu G; Meininger CJ
Biofactors; 2009; 35(1):21-7. PubMed ID: 19319842
[TBL] [Abstract][Full Text] [Related]
59. The role of the L-arginine/nitric oxide pathway in myocardial ischaemic and reperfusion injury.
Pernow J; Wang QD
Acta Physiol Scand; 1999 Oct; 167(2):151-9. PubMed ID: 10571551
[TBL] [Abstract][Full Text] [Related]
60. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
